entertainment -WSS

entertainment

author：entertainment 2025-10-02 10:48:40 - browse：32

A dosage of Wegovy, a drug used for weight loss — Amanda Andrade-Rhoades/AP

U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment.

The new label indicates that Wegovy can be used to reduce the risk of major heart complications — including heart attack, stroke, or cardiovascular-related deaths — for people with overweight or obesity and existing heart disease, Novo said in a statement Friday.

The decision was based on results of a large, five-year trial that showed Wegovy cut the risk of cardiovascular problems by 20% in that population. This is the first time a weight loss treatment has been approved to also help improve heart outcomes, the FDA said.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Listen: Your guide to Wegovy's blockbuster heart study

knowledge

focus

WSS

Reporting on presidential health from Reagan to Trump and Biden

Presidential candidate assassinated in Ecuador, 1 suspect dead and 6 arrested

The perfect storm of weather conditions that led to the devastating wildfires in Maui

Readout Newsletter: Sarepta, Alnylam, and Royalty Pharma

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

Newly revealed memo details efforts to keep Trump in power following election loss

hotspot

entertainment

Wikipedia

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Walensky prepares to leave CDC — and Congress — behind

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

AbbVie CEO Gonzalez to step down after a decade fiercely defending Humira

In age of alternative facts, a scholarly course on calling out crap

An innovative path out of biotech’s “valley of death”

State Dept. review finds Biden bears some blame for Afghanistan failures

TB outbreak tied to bone grafts underscores testing shortcomings

explore

The history of OxyContin, told through Purdue Pharma documents

NYC stabbing: Teen named, arraigned by District Attorney in O'Shae Sibley death

After John Oliver segment, STAT readers share their opioid

Elevance, SCAN deals highlight health insurer acquisition scrutiny

New study raises questions about niacin and heart health

Weight loss drugs aren’t covered by Obamacare. That may change

focus

knowledge

focus

leisure time